November 5th, 2020 at the following time:
1:00PM - 4:00PM Eastern Time


Eyenovia, Inc. (NASDAQ: EYEN) is a NDA stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics with its Optejet® dispenser. Eyenovia's pipeline is currently focused on unique medications for pediatric myopia, presbyopia and mydriasis. Eyenovia recently out-licensed the development and commercialization of an investigational microdose formulation of atropine ophthalmic spray, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12, to Bausch Health and Arctic Vision, in exchange for upfront and milestone payments and a royalty stream. Another program, Mydcombi™, a unique fixed combination of two mydriasis drugs with a “no touch” Optejet dispenser, is anticipated to result in an NDA submission by the end of 2020. Lastly, MicroLine for improvement of near vision is anticipated to start phase 3 studies by the end of 2020 and have topline results in early 2021.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.


"Eyevensys is a France-based, VC-backed biotech company, also incorporated in USA. Eyevensys is developing a novel non-viral gene therapy for treatment of ocular diseases. The technology is comprised of a proprietary device that delivers plasmid DNA to the ciliary muscle. After electro-transfection, the muscle cells sustainably produce the therapeutic proteins that the plasmid encodes.

The company has successfully completed part 1 of it's clinical safety study in France and the UK, enrolling 9 patients with late stage non-infectious uveitis. Study is being expanded in less severe patients - An IND is being filed in USA in order to validate technology in a Phase 2 Clinical study -non-infectious uveitis .

Parallel programs are pursued with different proteins-one for treatment of retinitis pigmentosa, one for Wet AMD"

Graybug Vision

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.

Kedalion Therapeutics

Kedalion Therapeutics is focused on revolutionizing the delivery of topical ocular medicine to significantly increase patient comfort and ease of use. Kedalion’s AcuStreamTM technology is being developed for delivery of topical drugs to the eye in a precise and accurate manner that will enable comparable therapy with an 80% reduction in dose relative to standard drops. The potential for reduced side effects and increased patient comfort is intended to transform the concept of simplicity, convenience and adherence in self-administered care for leading ocular diseases.


LayerBio is a clinical-stage biotech company developing its novel OcuRing™ technology for drop-less cataract surgery. LayerBio was formed as a spin-off from the laboratory Dr. Paula Hammond at MIT. LayerBio recently completed a Phase 1 study demonstrating safety and efficacy of the OcuRing-K™ (ketorolac) for prevention of postoperative inflammation in patients undergoing cataract surgery. We are currently seeking strategic partners and investors to advance our first product through clinical development and support expansion of the OcuRing™ platform.


PolyActiva Pty Ltd is a privately held clinical-stage biotechnology company seeking to develop sustained release implants for the treatment of a range of ocular diseases, including glaucoma, ocular inflammation, macular edema and intraocular infections. The implants are derived from a common polymeric prodrug platform technology. The initial focus is on developing implants with clinically proven drug therapies. PolyActiva’s first asset, PA5108, is an ocular implant for the treatment of glaucoma that provides 6-months therapy by releasing a constant daily dose of latanoprost free acid and then biodegrades within 6-weeks of the end of therapy. The PA5108 ocular implant successfully completed its first clinical study and is currently being evaluated in a Phase 2 dose ranging study. On the back of recent clinical demonstration of the safety of the technology platform, PolyActiva is preparing to expand its pipeline of assets into other therapeutic areas, including delivery to the back of the eye.

Re-Vana Therapeutics

"Re-Vana Therapeutics Ltd, founded in 2016 as a spin out from Queen’s University Belfast, Northern Ireland, is a specialty ocular therapeutic and drug delivery company with the main office located in Belfast and a U.S. office based in Tampa, Florida. Re-Vana is focused on the development of internal sustained release biologic and small molecule therapeutics as well as external strategic collaborations with industry. Re-Vana closed its oversubscribed Pre-series A financing round in June 2020. This financing was the first time in which all three specialized U.S. ophthalmic funds ExSight Ventures, InFocus Capital and Visionary Ventures invested in the same ophthalmic company.

In 2019, Re-Vana also secured funding from Innovate U.K. totaling more than $400K to support the development of a sustained release drug. Additionally in 2020, the Company entered into a strategic feasibility collaboration with a leading global pharmaceutical company for a novel therapeutic."


TALLC Inc. is preclinical company leveraging its range of new mechanism drug candidates combined with its proprietary SmartCelle(TM) smart micelle, and AmyloFlex(TM) bioabsorbable controlled release platform technologies, to generate valuable new medicines for the eye. While developing slow release formulations to address chronic diseases such as dry AMD, Dry-Eye and Glaucoma we intend first to address front of eye conditions.